Rocket Pharmaceuticals' Gene Therapy Trial for Danon Disease Faces FDA Hold After Patient Death
TL;DR Summary
Rocket Pharmaceuticals announced an update on its Phase 2 trial of RP-A501 for Danon disease after a patient experienced a serious adverse event and subsequently passed away, leading to a clinical hold by the FDA. The company is investigating the cause, working with regulators and stakeholders, and has paused dosing to ensure patient safety. The trial aims to evaluate the efficacy of RP-A501, a gene therapy targeting cardiac function in Danon disease, with ongoing efforts to resume the study.
Topics:business#biotechnology#clinical-trial#danon-disease#gene-therapy#rocket-pharmaceuticals#rp-a501
- Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease Business Wire
- Rocket crashes as gene therapy patient dies, FDA imposes hold Fierce Biotech
- FDA hold after patient death in study of Rocket's gene therapy for Danon disease FirstWord Pharma
- Participant in Rocket Pharmaceuticals gene therapy study dies statnews.com
- RCKT stock plunges to 52-week low, hitting $2.32 Investing.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
8 min
vs 9 min read
Condensed
96%
1,771 → 79 words
Want the full story? Read the original article
Read on Business Wire